Opinion|Videos|October 28, 2024
First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient
Panelists discuss how their clinical experience with ESA failure rates and timelines compares with reported outcomes in large community practice studies, and how they counsel patients on the choice between luspatercept and ESAs as first-line therapy for lower-risk MDS, incorporating patient preferences and patient-reported outcomes from recent clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please describe: In your clinical practice, what percentage of your patients have disease that fails ESA? What is the general time frame where you may see ESA failure?
- How does this compare with reported ESA outcomes? Resource link: Gordan L, et al. LR-MDS large US community practice: pt outcomes post ESA Tx. EHA 2024 abstract.
- Please describe what you typically counsel and/or share with your patients when considering luspatercept vs ESA as first-line therapy for LR-MDS. How do you take into consideration the patient’s preference
Resource link: Olivia EN, et al. Patient-reported outcomes from COMMANDS study. ASH 2023 abstract.
Advertisement
Related to this article
Alternating VR-CAP and rituximab plus cytarabine with continuous acalabrutinib produced deep responses and high MRD negativity in untreated MCL.
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
The OncFive: Top Oncology Articles for the Week of 8/30
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know
5